These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26177791)

  • 21. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
    Deng J; Feng Z; Li Y; Pan T; Li Q; Zhao C
    Medicine (Baltimore); 2018 Nov; 97(47):e13341. PubMed ID: 30461654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass.
    Felsenberg D; Bock O; Börst H; Armbrecht G; Beller G; Degner C; Stephan-Oelkers M; Schacht E; Mazor Z; Hashimoto J; Roth HJ; Martus P; Runge M
    J Musculoskelet Neuronal Interact; 2011 Mar; 11(1):34-45. PubMed ID: 21364273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
    Ralston SH; Binkley N; Boonen S; Kiel DP; Reginster JY; Roux C; Chen L; Rosenberg E; Santora A;
    Calcif Tissue Int; 2011 Jun; 88(6):485-94. PubMed ID: 21479913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
    Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate.
    Szymczak J; Bohdanowicz-Pawlak A
    Horm Metab Res; 2013 Sep; 45(10):759-64. PubMed ID: 23888411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women.
    Macdonald HM; Wood AD; Aucott LS; Black AJ; Fraser WD; Mavroeidi A; Reid DM; Secombes KR; Simpson WG; Thies F
    J Bone Miner Res; 2013 Oct; 28(10):2202-13. PubMed ID: 23585346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ; Im JA; Kim SH
    Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.
    Brown TT; Ross AC; Storer N; Labbato D; McComsey GA
    Antivir Ther; 2011; 16(7):1063-72. PubMed ID: 22024522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
    Bone HG; Downs RW; Tucci JR; Harris ST; Weinstein RS; Licata AA; McClung MR; Kimmel DB; Gertz BJ; Hale E; Polvino WJ
    J Clin Endocrinol Metab; 1997 Jan; 82(1):265-74. PubMed ID: 8989272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
    Recker R; Lips P; Felsenberg D; Lippuner K; Benhamou L; Hawkins F; Delmas PD; Rosen C; Emkey R; Salzmann G; He W; Santora AC
    Curr Med Res Opin; 2006 Sep; 22(9):1745-55. PubMed ID: 16968578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.
    Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Harris DR; Price G; Baker A; Meyer WA; Wilson CM; Hazra R; Kapogiannis BG; Mulligan K;
    Clin Infect Dis; 2018 Jan; 66(2):220-228. PubMed ID: 29020329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.
    Olmos JM; Hernández JL; Llorca J; Nan D; Valero C; González-Macías J
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4491-7. PubMed ID: 23043189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
    Adachi JD; Saag KG; Delmas PD; Liberman UA; Emkey RD; Seeman E; Lane NE; Kaufman JM; Poubelle PE; Hawkins F; Correa-Rotter R; Menkes CJ; Rodriguez-Portales JA; Schnitzer TJ; Block JA; Wing J; McIlwain HH; Westhovens R; Brown J; Melo-Gomes JA; Gruber BL; Yanover MJ; Leite MO; Siminoski KG; Nevitt MC; Sharp JT; Malice MP; Dumortier T; Czachur M; Carofano W; Daifotis A
    Arthritis Rheum; 2001 Jan; 44(1):202-11. PubMed ID: 11212161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.